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Abstract
Background/Aims: Atherosclerotic renal artery stenosis (ARAS) is frequently detected in 
patients with resistant hypertension (RHTN), but the evidence supporting the utility of renal 
revascularization in these patients is limited. This prospective, observational study investigates 
the outcomes of renal stenting in patients with RHTN and hemodynamically significant 
ARAS. Methods: Fifty-four patients with RHTN were selected because of angiographic 
evidence of ARAS >70% and were followed for 4 years after renal stenting. Renal function 
and echocardiographic variables were assessed at baseline and during follow-up. Results: 
Blood pressure decreased rapidly after renal stenting and was normalized in 67% of patients 
at six months, with significant reduction in the number of antihypertensive drugs. Creatinine 
clearance increased in 39% of patients, decreased in 52%, and remained stable in the remaining 
9%, with an average value that had a nonsignificant decrease during follow-up. Urinary 
albumin excretion did not change throughout the study. After 4 years, left ventricular (LV) wall 
thickness and concentric geometry decreased significantly and variables of LV diastolic function 
improved. Conclusion: In patients with RHTN, stenting of hemodynamically significant ARAS 
decreases blood pressure, preserves renal function in a substantial proportion of patients, and 
improves LV structure and function, suggesting the opportunity for timely identification of 
ARAS in these patients.
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Introduction
Hypertension is defined as resistant to treatment when two antihypertensive agents 
plus a diuretic at adequate doses fail to lower blood pressure values below 140/90 mm 
Hg. Resistant hypertension has a prevalence that approximates 10% within the overall 
hypertensive population [1] and is associated with a relatively more severe cardiac and renal 
damage [2, 3]. Resistant hypertension might originate from different conditions including 
characteristics of lifestyle, obstructive sleep apnoea, advanced hypertensive organ damage, 
and previously undetected forms of secondary hypertension [4]. Among the latter conditions, 
chronic renal failure, primary aldosteronism and renovascular hypertension (RVH) caused 
by atherosclerotic renal artery stenosis (ARAS) are the most frequent. The prevalence of 
ARAS in the elderly population is comprised from 5 to 10% [5] and steadily increases in 
patients undergoing different types of angiographic examinations [6]. In addition to RVH, a 
possible consequence of ARAS is ischemic nephropathy that might be a relevant cause of renal 
failure [7] and need for dialysis [8]. For these reasons, timely identification and correction 
of ARAS might modify the natural history of the disease with possible benefits for both renal 
and cardiovascular outcomes [9]. However, while a multiplicity of observational studies on 
revascularization of stenotic renal arteries reported a significant reduction in blood pressure 
and plasma creatinine, randomized controlled trials that compared renal artery angioplasty 
with stenting to conservative treatment did not meet the expectations as they could not 
demonstrate any benefit on renal and cardiovascular outcomes [10]. These randomized 
trials have been criticized on several grounds and principally for inadequate selection of 
patients [11]. Indeed, the majority of these studies enrolled patients with a relatively mild 
degree of renal arterial narrowing or excluded patients at higher cardiovascular risk such 
as those with resistant hypertension. Although ARAS is frequently detected in patients 
with resistant hypertension [12], the evidence supporting the clinical utility of renal artery 
revascularization in these patients is limited because none of the previous studies focused 
on these specific patients and data currently available originate mostly from subgroup 
analyses. Moreover, only a few studies have examined in these patients the possible benefits 
of renal artery revascularization on hypertension-related cardiac changes and albuminuria. 
The aim of the present study was therefore to investigate prospectively and in the long-term 
the clinical, cardiac, and renal outcome of renal revascularization in patients with resistant 
hypertension and angiographic evidence of hemodynamically significant ARAS. 
Materials and Methods
Patients
Fifty-four patients (age 69±9 y.; 39 males, 15 females) with resistant hypertension and hemodynamically 
relevant ARAS detected at renal artery angiography were included in a long-term, observational, 
prospective study on the effects of renal revascularization with angioplasty and stenting. Patients were 
consecutively recruited between January 2002 and December 2011 among patients with hypertension 
resistant to treatment who were referred for evaluation at the Hypertension clinic of the University of 
Udine. Blood pressure was measured in the sitting position by a validated automated device (Omron M6, 
OMRON Healthcare Co., Kyoto, Japan) after each patient had been supine for 15 min and the average of three 
readings obtained in 5 min was recorded [13]. Resistant hypertension was defined according to established 
guidelines when systolic blood pressure was ≥140 mm Hg and/or diastolic blood pressure was ≥90 mm Hg 
in patients who were treated with three or more different antihypertensive agents that included a diuretic, 
at appropriate doses [13]. Predefined exclusion criteria were age younger than 40 years or older than 80 
years, renal failure with 24-hour creatinine clearance ≤30 ml/min/1.73 m2, urinary protein excretion ≥0.5 
g/day, congestive heart failure, and any other known renal disease. In all patients, pseudo-resistance (non-
adherence to medication, white-coat hypertension, lifestyle) was ruled out with standardized procedures. 
To investigate the cause of resistant hypertension, all patients seen at the clinic are routinely screened with 
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clinical and laboratory testing that include analysis of medical records and adherence to treatment, physical 
examination, urine analysis, blood biochemistries, duplicate measurements of 24-hour creatinine clearance 
and urinary sodium excretion, plasma active renin and aldosterone, urinary cortisol and catecholamines, 
electrocardiogram, echocardiography, polysomnography, renal ultrasound with duplex Doppler examination 
of intrarenal vessels, and renal angio-CT scan or angio-MRI [14]. Renal angiography was performed in all 
patients in whom increased intrarenal duplex systolic velocity was detected and/or renal artery stenosis 
was demonstrated either at angio-MRI or angio-CT scan [15]. Patients were classified as smokers if they 
had smoked for at least 5 years, and up to 1 year before the study. Dyslipidemia was defined by a non-HDL 
cholesterol ≥130 mg/dl and/or as current use of lipid-lowering medication [16]. Prevalence of coronary 
heart, cerebrovascular, and peripheral artery disease was also defined in all patients, as previously reported 
[17].
Prospective study
Hemodynamically significant ARAS was defined by angiographic demonstration of renal artery 
stenosis >70% in one or more major renal vessels [18] and was detected in 54 patients. Patients with 
lesser degrees of renal artery narrowing were excluded. No patient had angiographic characteristics of 
fibromuscular dysplasia or other types of renal artery disease. All the patients included in the prospective 
study were white, lived in the north-east of Italy, and were representative of the hypertensive population 
in this area [19]. Patients underwent renal artery revascularization by performing angioplasty with bare 
metal stenting of the stenotic renal artery. All procedures were performed by femoral approach according 
to standard interventional techniques. In patients with bilateral stenoses, both vessels were treated 
in a single procedure. Procedural success was defined as residual stenosis of less than 20%. Before the 
procedure, combined oral antiplatelet therapy was begun with aspirin (325 mg) and clopidogrel (300 mg). 
All patients were subsequently assigned to continuous treatment with aspirin (125 mg q.d.) with addition 
of clopidogrel (75 mg q.d.) for the first 6 months. Clinical and biochemical evaluations were performed 
after revascularization at 3 weeks, 6 months and 4 years. Antihypertensive treatment was adjusted to 
reach blood pressure values ≤140/90 mm Hg in quarterly visits during the first year and in yearly visits 
thereafter. Angiotensin-converting enzyme inhibitors or angiotensin II-receptor antagonists were used as 
the initial therapeutic choice with subsequently ordered addition of a thiazide diuretic, a dihydropyridine 
calcium-channel blocker, and a beta-blocker. The study was conducted in accordance with the principles of 
the Declaration of Helsinki and received approval from the Institutional Review Board. Informed consent 
was obtained from all patients. 
Echocardiography
Cardiac ultrasound examination was performed by the same experienced operator who was unaware 
of the patients’ clinical and laboratory characteristics [20]. Measurements of left ventricular (LV) internal 
dimensions and wall thickness were obtained with the patient in the partial left decubitus position with 
a commercial machine (Aplio CV, Toshiba Medical System, Tokyo, Japan) and a 2.5 MHz transducer, under 
bi-dimensional cross-sectional control and simultaneous electrocardiographic tracing. The LV geometric 
pattern was defined by the ratio of end-diastolic posterior LV wall thickness to one-half end-diastolic LV 
internal dimension (RWT). LV mass index (LVMI) was calculated by the Penn Convention formula and 
normalized for body surface area. Systolic function was estimated by the ejection fraction (EF) and both 
endocardial and midwall fractional shortening (FS), with the latter taking into account epicardial migration 
of the midwall during systole. Pulsed Doppler recordings at the level of the mitral valve tips were obtained 
from apical four-chambers scans to measure early and late wave diastolic filling velocities, their ratio (E/A 
ratio), early-wave deceleration time, and isovolumic relaxation time.
Laboratory measurements
A sample of venous blood was obtained from each patient in the sitting position in the morning after an 
overnight fast and without venous stasis. Blood was collected into silicone-treated glass tubes, where it was 
mixed with 10% of its volume of 0.1 mmol/l tri-sodium citrate and immediately centrifuged at 1, 700g for 
20 min at 4°C. Plasma was separated and frozen at -80 °C until being assayed, usually within one month after 
sampling. Plasma lipids measurement was performed as reported previously [21]. Plasma concentrations 
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of lipoprotein(a) were determined by the Macra® Lp(a) Enzyme Linked Immunosorbent Assay (ELISA) 
kit (Trinity Biotech PLC, Bray, Ireland) [21]. Active renin was assayed without previous antihypertensive 
drug washout by chemiluminescence enzyme immunoassay (CLIA) and plasma aldosterone was assayed 
by radioimmunoassay in plasma samples that were obtained with patients in the sitting position [22]. 
Creatinine clearance was assessed by duplicate 24-hour collections and normalized for body surface area. 
Albuminuria was measured in duplicate 24-hour urine collections by immunoturbidimetric method using a 
commercial kit with an analyzer ALBT2 (Tina-quant Albumin Gen.2, Roche/Hitachi, Mannheim, Germany) 
[23]. The limit of detection was 3 mg/l and the coefficient of variation between 0.7% and 1.9%.
Statistical analysis
Data are presented as mean ± SD for variables with normal distribution and as median (inter-quartile 
range) for skewed variables. Normally distributed variables were compared with the Student’s t test. 
Variables with skewed distribution were analysed after logarithmic transformation. One-way analysis of 
variance was used to compare variables at different time-points after renal revascularization. Relationships 
between continuously distributed variables were examined by linear regression analysis. Two-tailed 
probability value of less than 5% was considered to indicate statistical significance. All data analyses were 
performed using Stata 9.2 (StataCorp LP, TX, USA).
Results
Five-hundred-sixty-eight patients with true resistant hypertension were screened at 
the clinic from January 2002 to December 2011. In 54 patients evidence of ARAS >70% 
was detected by angiography. Among patients with ARAS, 2 had bilateral stenosis and the 
remaining 52 had unilateral stenosis of the main renal artery. The clinical characteristics 
and comorbidities of patients with ARAS are shown in Table 1. A relevant proportion of 
patients smoked and had dyslipidemia and/or diabetes. More than one third of patients 
had coronary artery and/or 
peripheral artery disease as 
comorbidities.
None of the patients 
was lost at follow-up. 
Both systolic (-17 mm Hg; 
11%) and diastolic (-9 mm 
Hg; 9%) blood pressure 
decreased significantly 3 
weeks after renal artery 
stenting and further 
significant decrease was 
observed at six months 
(Table 2). At six months, 
blood pressure was 
normalized (<140/90 
mm Hg) in 36 (67%) of 54 
patients and the average 
number of antihypertensive 
drugs was significantly 
reduced from baseline 
(2.1 vs. 3.4, respectively). 
Blood pressure levels 
and the number of 
antihypertensive drugs 
remained comparable in 
Table 1. Clinical characteristics of hypertensive patients with resistant 
hypertension and atherosclerotic renal artery stenosis. Values are 
expressed as mean ± SD
   Characteristics Patients  (n=54) Age, years [range] 69±9 [43-80] Males, n (%) 35 (65) Body mass index, kg/m2 28.0±5.5 Systolic blood pressure, mm Hg [range] 161±20 [125-200] Diastolic blood pressure, mm Hg [range] 97±13 [70-130] Pulse pressure, mm Hg 57±15 Duration of hypertension, years [range] 15±10 [1-29] Antihypertensive drugs, n [range] 3.4±0.6 [3-5] Diuretics, n (%) 29 (54) Beta blockers, n (%) 32 (59) Calcium channel blockers, n (%) 29 (54) ACE inhibitors, n (%) 15 (28) Angiotensin II receptor blockers, n (%) 20 (37) Alpha blockers, n (%) 11 (20) Smokers, n (%) 17 (31) Diabetes, n (%) 12 (22) Dyslipidemia, n (%) 35 (65) Coronary artery disease, n (%) 18 (33) Cerebrovascular disease, n (%) 6 (11) Peripheral artery disease, n (%) 22 (41)              
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the long-term follow-up when blood pressure was normalized in 48 (89%) patients. Plasma 
renin levels decreased significantly 3 weeks after renal revascularization and did not change 
significantly thereafter, whereas plasma aldosterone levels did not change significantly 
throughout the study. No significant changes were observed in plasma glucose, lipids, 
and uric acid levels during follow-up. After renal artery revascularization, 24-h creatinine 
clearance increased in 21 (39%) patients, decreased in 28 (52%) and remained stable in 
Table 2. Blood pressure, blood biochemistries, and renal function in 54 patients with resistant hypertension 
and atherosclerotic renal artery stenosis at baseline and during follow-up after renal artery stenting. Values 
are expressed as mean ± SD. Comparisons were done by analysis of variance and P values indicate differences 
of variables across the study. UACR, urinary albumin/creatinine ratio; IQR, interquartile range Variable Baseline 3 weeks 6 months 4 years P Systolic blood pressure, mm Hg [range] 161±20 [125-200] 144±15 [125-165] 135±10 [120-155] 139±14 [115-170] <0.001 Diastolic blood pressure, mm Hg [range] 97±13 [70-130] 88±10 [60-105] 85±11 [60-100] 85±8 [60-95] <0.001 Antihypertensive drugs, n [range] 3.4±0.6 [0-5] 2.0±1.6 [0-4] 2.1±1.3 [0-4] 2.6±1.4 [0-5] <0.001 Glucose, mg/dl 104±33 - 99±17 110±26 0.095 Total cholesterol, mg/dl 180±40 - 180±57 176±41 0.876 HDL-cholesterol, mg/dl 52±12 - 48±15 50±14 0.320 LDL-cholesterol, mg/dl 103±32 - 106±35 100±32 0.641 Trigycerides, mg/dl 130±63 - 146±89 123±64 0.248 Lipoprotein(a), mg/dl 22±20 - 20±14 19±13 0.611 Uric acid, mg/dl 6.1±1.3 - 6.0±1.1 6.2±1.3 0.703 Active renin, UI/ml 51±74 15±14 - 28±23 <0.001 Aldosterone, pg/ml 178±95 153±93 - 188±130 0.561 Creatinine, mg/dl 1.25±0.38 1.25±0.32 1.28±0.33 1.39±0.25 0.080 24-h creatinine clearance, ml/min/1.73 m2 81±48 77±34 76±31 72±27 0.633 Urinary albumin excretion, mg/d 119±39 121±39 115±43 120±35 0.865 UACR, mg/g [IQR] 84 [53-148] 91 [59-162] 86 [52-157] 89 [55-165] 0.833                 
 
  
Table 3. Echocardiographic variables in 54 patients with resistant hypertension and atherosclerotic renal 
artery stenosis at baseline and during follow-up after renal artery stenting. Values are expressed as mean ± 
SD. Comparisons were done by analysis of variance and P values indicate differences of variables across the 
study. LV, left ventricular Variable Baseline 6 months 4 years P LV end-diastolic diameter, mm 51±7 52±7 51±5 0.439 LV end-systolic diameter, mm 32±6 30±6 31±5 0.192 Interventricular septum, mm 11.3±2.2 10.9±1.9 9.8±2.0 <0.001 Posterior wall, mm 10.6±1.7 10.6±1.8 9.5±1.4 <0.001 LV mass, g 205±76 201±75 186±50 0.313 Indexed LV mass, g/m2 111±37 110±38 101±26 0.248 Relative wall thickness, % 0.429±0.081 0.413±0.083 0.378±0.077 0.041 LV ejection fraction, % 67±8 66±8 66±6 0.720 LV fractional shortening, % 38±7 37±8 40±8 0.502 Left atrial diameter, mm 44±9 45±7 41±8 0.029 E/A ratio 0.83±0.28 0.81±0.29 0.96±0.34 0.023 E wave deceleration time, msec 234±68 234±71 237±70 0.967 Isovolumic relaxation time, msec 88±24 90±25 94±25 0.439     
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the remaining 5 (9%) with an average value that had a small and nonsignificant decrease at 
the end of follow-up. Urinary albumin excretion did not change significantly in any patient 
throughout the study.
Echocardiographic variables of patients with ARAS that were measured at baseline 
and during follow-up are summarized in Table 3. No significant changes in LV internal 
dimensions, mass, geometry, systolic and diastolic function were observed at 6 months after 
renal artery revascularization. At the end of the long-term follow-up, interventricular septum 
and LV posterior wall thickness were significantly reduced and the average LV mass index 
was decreased but not significantly (-10 g/m2). Also, the LV RWT was significantly decreased 
indicating reversal of the concentric pattern of LV geometry. No significant changes were 
observed in LV systolic function, whereas a significant reduction of left atrial diameter and 
increase in the E/A ratio indicated significant improvement of the LV diastolic function.
Univariate correlation analysis was used to examine the possible relationships between 
clinical (age, BMI, blood pressure, duration of hypertension) and biochemical (plasma 
glucose, lipids, uric acid, renin, aldosterone, creatinine clearance) variables that were 
measured at baseline and the changes in blood pressure, echocardiographic, and renal 
variables that were observed after renal artery revascularization. This analysis did not 
detect any significant relationships.
Discussion
Results of randomized clinical trials indicate that revascularization of ARAS does not 
confer any significant benefit over medical therapy [10, 24]. However, these trials have been 
broadly criticized because of criteria used for patients’ selection and, as suggested by many 
observational studies, timely identification and treatment of ARAS might modify the natural 
history of disease at least in some of these patients. The challenge is therefore to define 
which patients with ARAS will potentially benefit from renal artery revascularization in 
terms of renal and cardiovascular protection [25] and specifically designed observational 
investigations could provide insight in specific groups of patients. The present study has been 
the first designed specifically to investigate the effects of renal artery stenting in patients 
with resistant hypertension and hemodynamically significant (>70%) ARAS free of advanced 
renal failure and overt proteinuria. Patients were followed with a rigorous protocol with 
standardized antihypertensive medications and long-term follow-up providing evidence of 
significant and persistent benefit on blood pressure levels. Creatinine clearance and urinary 
albumin excretion remained unchanged after renal artery revascularization whereas, in 
the long-term, hypertension-related cardiac abnormalities were affected by treatment with 
significant decrease of LV wall thickness and concentric geometry, and improvement of LV 
diastolic function.
Previous retrospective and prospective observational studies reported the benefits 
of renal artery revascularization in terms of blood pressure decrease and renal protection 
in patients with ARAS ≥50% [26, 27] even when this was associated with uncontrolled 
hypertension [28-30]. In a registry of 265 patients with angiographic evidence of ARAS 
≥50%, a subgroup of whom had uncontrolled systolic hypertension, average blood pressure 
fell in a follow-up of 2 years from 160/86 mm Hg to 135/75 mm Hg [28]. Approximately 
half of patients in the registry had improved glomerular filtration suggesting that renal 
revascularization could preserve renal function in a substantial proportion. The HERCULES 
trial examined prospectively 202 patients with ARAS, 70% of whom had uncontrolled blood 
pressure (≥140/90 mm Hg) despite being on 3 or more antihypertensive agents [29]. In 
a 3-year follow-up, systolic blood pressure decreased by 16 mm Hg with no changes in 
the average number of antihypertensive drugs. However, in a retrospective analysis of 
32 patients with refractory hypertension and ARAS ≥50% who underwent renal artery 
revascularization, Ritchie et al. did not observe any benefit on mortality, cardiovascular 
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events, or end-stage renal disease during a follow-up of 3.8 years, in comparison to patients 
treated conservatively [30]. Additional observational studies lasting from 6 to 15 months 
examined the renal outcome of renal artery revascularization of ARAS in patients without 
resistant hypertension and reported a significant decrease in blood pressure levels with no 
changes in glomerular filtration [26, 27] or urinary albumin excretion [31, 32]. The results 
of the present prospective study further support the benefits on blood pressure control and 
preservation of renal function that can be obtained with renal artery stenting and extends the 
evidence to patients with hemodynamically significant ARAS who were identified because of 
resistant hypertension.
Cross-sectional investigations have demonstrated that hypertension-related cardiac 
abnormalities are significantly more frequent in patients with renal artery stenosis 
than matched patients with essential hypertension [33, 34]. Moreover, longitudinal 
assessment of cardiac structural and functional changes in patients with ARAS who were 
treated conservatively for 1 year demonstrated progression of these changes despite 
significant decrease in blood pressure [35]. Past studies addressed the effects of renal 
artery revascularization in hypertensive patients with renal artery stenosis (either ARAS 
or fibromuscular dysplasia) detected at angiography. Symonides et al. reported significant 
reduction of LV mass in 44 patients with either ARAS or fibromuscular dysplasia who 
underwent either surgical or percutaneous revascularization [31]. Similar reduction of LV 
mass was reported after renal artery stenting by Rzeznik et al [36]. and Zeller et al [37]. in 
a 1-year and 2-year follow-up study, respectively. Our study was conducted in patients with 
resistant hypertension and ARAS and demonstrates that successful renal artery stenting 
is followed, in the long-term, by reduction of LV mass that is associated with significant 
improvement of LV diastolic function.
Only a critical degree of renal artery stenosis can cause renal ischemia sufficient 
to activate the renin-angiotensin system and thereby hypertension, eventually leading 
to renal impairment. Although there is no established consensus on the degree of renal 
artery stenosis that justifies revascularization, the majority of previous observational and 
randomized studies used a 50% diameter stenosis as inclusion criterion [10]. However, it 
is known that due to compensatory intrarenal hemodynamics occurrence of reduced renal 
perfusion pressure with subsequent activation of the renin-angiotensin system requires 
renal arterial narrowing of more than 70% [38]. For these reasons the present study 
included only patients with this degree of renal artery stenosis. Moreover, the evidence of 
a hemodynamically relevant stenosis in our patients was supported by the demonstration 
of highly significant reduction of plasma renin levels that despite use of antihypertensive 
agents, occurred 3 weeks after renal stenting.
Some limitations of this study need to be highlighted. First, this is an observational 
study and, as such, cannot provide any insight on the value of renal stenting in comparison 
to conservative treatment. Second, use of a clinic sample might limit the possibility to 
extend conclusions to a more general setting because of a possible bias due to the referral 
of patients to the source of care. Third, because we did not find any associations between 
clinical and biochemical variables measured at baseline and changes in blood pressure and 
echocardiographic variables observed after renal stenting, statistical limitations in detection 
of these associations due to the size of the study (beta-error) cannot be excluded. Last, 
systematic use of ambulatory blood pressure monitoring during follow-up would have been 
useful to obtain better assessment of blood pressure changes induced by treatment. The 
strengths of this study include inclusion of a selected population of patients with resistant 
hypertension and evidence of hemodynamically significant ARAS, the rigorous treatment 
protocol that was used after renal stenting, and the duration of follow-up.
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Conclusion
In patients with hypertension resistant to treatment and evidence of hemodynamically 
significant ARAS renal stenting decreases blood pressure, preserves renal function in 
a substantial proportion of patients, and improves LV structure and function in the long-
term. These results indicate that negative results of randomized controlled trials of renal 
stenting performed in settings different from resistant hypertension should not withheld 
proper diagnostic evaluation for possible ARAS in these patients. Timely identification and 
correction of ARAS in patients with resistant hypertension could modify the natural history 
of the disease with significant benefits for both renal and cardiovascular outcomes.
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